5-Mark Detailed Answers

1. Staphylococcal Scalded Skin Syndrome (SSSS)
2. Taenia capitis (Tinea capitis) and its management
3. MDR in Leprosy
4. Scabies - Management

SHORT NOTE 1: Staphylococcal Scalded Skin Syndrome (SSSS)

Definition

Etiology & Pathogenesis

• Caused by exfoliative toxins A and B (ETA and ETB) produced by Group 2 Staphylococcus aureus, phage types 71 or 55
• The bacteria reside at a distant focus (pharynx, nose, ear, conjunctiva) - the skin lesions themselves are sterile
• Toxins specifically cleave desmoglein-1 (the same target as pemphigus foliaceus autoantibodies), causing a split below the granular layer of the epidermis
• Since mucous membranes have predominantly desmoglein-3 (not desmoglein-1), they are characteristically spared

Clinical Features

• Abrupt onset with skin redness and tenderness in periorificial areas (around eyes, nose, mouth) and intertriginous areas (neck, groin, axillae)
• Fever (variable), intense skin tenderness simulating a sunburn
• Nikolsky sign is positive - skin slips off with gentle lateral pressure
• Large sheets of epidermis separate (exfoliation in sheets)
• Sparing of palms, soles, and mucous membranes - key distinguishing feature from TEN
• Blisters form easily where pressure is applied (e.g., ECG lead placement)

Diagnosis

• Clinical - primarily
• Frozen section biopsy of blister roof: cleavage is below the granular layer (superficial) - NOT full-thickness necrosis as seen in TEN
• Cultures from primary site of infection (nares, perianal, periocular areas) - NOT from skin lesions (they are sterile)
• Differentiated from Stevens-Johnson Syndrome/TEN: SSSS has no mucosal involvement, more superficial split, affects younger patients

Treatment

• First-line: Penicillinase-resistant penicillin (e.g., dicloxacillin or cloxacillin) + IV fluids + supportive care
• Clindamycin may be added (inhibits toxin production via ribosomal mechanism), but only if culture shows susceptibility (resistance is increasing)
• Wound care and fluid replacement (similar to burn management)

SHORT NOTE 2: Tinea Capitis (Taenia Capitis) and its Management

Definition

Epidemiology

• Most common in children aged 3-14 years
• Reduced after puberty due to fungistatic fatty acids in sebum
• More common in children of African descent
• Spread via fomites (combs, caps, pillowcases); hairs can harbor organisms for >1 year
• Causative organisms: T. tonsurans (most common in USA/UK), M. canis (most common in Europe)

Clinical Types

Diagnosis

• KOH mount of hair stubs: ectothrix vs endothrix pattern
• Wood's lamp: green fluorescence (Microsporum species)
• Fungal culture (gold standard) on Sabouraud's dextrose agar
• Dermoscopy: comma hairs, corkscrew hairs

Management

• Griseofulvin (oral) - drug of choice, especially in children: 20-25 mg/kg/day for 6-8 weeks (ultramicronized form)
• Terbinafine (oral) - preferred for Trichophyton species, 4 weeks
• Itraconazole or Fluconazole as alternatives
• Adjunct: Selenium sulfide or ketoconazole shampoo (2-3x/week) to reduce shedding and transmission
• Treat household contacts and screen carriers

SHORT NOTE 3: MDR in Leprosy

Background

Standard MDT Regimen (WHO 1982)

Definition of MDR Leprosy

Mechanisms of Resistance

• Dapsone resistance: Mutations in folP1 gene (dihydropteroate synthase)
• Rifampicin resistance: Mutations in rpoB gene (RNA polymerase beta subunit)
• Fluoroquinolone resistance: Mutations in gyrA/gyrB genes

Management of MDR Leprosy

1. Ofloxacin (or other fluoroquinolones)
2. Minocycline
3. Clarithromycin

Leprosy Reactions (Management)

• Type 1 (Reversal reaction): Prednisone 1-2 mg/kg/day in tapering doses over ~3 months
• Type 2 (ENL): Thalidomide 100-400 mg/day (first-line); prednisolone for women of childbearing age
• Methylprednisolone pulse IV for severe nerve damage

SHORT NOTE 4: Scabies - Management

Causative Agent

Clinical Features (briefly)

• Intense nocturnal pruritus (due to sensitization to mite antigens)
• Pathognomonic burrows in web spaces of fingers, wrists, genitalia, periareolar area
• Nodular scabies: persistent pruritic nodules on scrotum/penis
• Crusted (Norwegian) scabies: in immunocompromised (HIV, steroids, neurologic disease) - hyperkeratotic, teeming with mites, minimally pruritic, highly contagious

Treatment

• Ivermectin 200 mcg/kg orally as a single dose, repeated after 1-2 weeks
• Drug of choice for crusted scabies (use oral + topical combination)
• Also useful in immunocompromised patients and institutional outbreaks

Additional Measures

• Treat all household contacts simultaneously (even if asymptomatic) - essential to prevent reinfestation
• Decontaminate clothing and bedding (wash in hot water >50°C or seal in plastic bag for 72 hours)
• Nodular scabies: intralesional steroids, tar preparations, or excision
• Crusted scabies: combination oral ivermectin + topical permethrin or benzyl benzoate; keratolytics (5% salicylic acid) to reduce crust

Post-treatment

• Pruritus may persist for 2-4 weeks after successful treatment (due to dead mites/antigens) - this does not indicate treatment failure
• Scabicide should not be repeated too early unless reinfestation is confirmed

Note: Topics (A) Multinucleated giant cells, (C) Dorsal root ganglion, (C) Post-herpetic neuralgia, (C) Nasociliary branch of ophthalmic nerve, and (B) Diabetes mellitus are also listed in your image. Let me know which of these you need detailed 5-mark answers for and I will cover them in the same depth!

Ulcerative Colitis - Surgical Management (In Detail)

Overview

Indications for Surgery

1. Failure of Medical Management (Most Common)

• Multiple bowel movements per day, urgency, tenesmus
• Poor nutritional status, failure to thrive, low body weight
• Very poor quality of life despite maximal medical therapy
• In children - failure to grow is a specific indication

• Bloody diarrhea >10 times/day
• Heart rate >90 beats/min
• Temperature >37.5°C
• Requirement for blood transfusion
• ESR >30 mm/hr

• Defined by 3 or more of: tachycardia >100, leukocytosis >12,000/dL, hypoalbuminemia <3 g/dL, temperature >38°C, transverse colon diameter >5 cm on plain X-ray
• NB: a dilated "megacolon" does NOT need to be radiologically present to meet this definition
• Risk of colonic perforation - requires urgent surgical intervention

2. Dysplasia and Colorectal Cancer

• UC patients have higher CRC risk; surveillance colonoscopy starts 8-10 years after disease onset, every 1-3 years
• Indications for surgery:
  • Multiple areas of low-grade dysplasia
  • High-grade dysplasia (any)
  • Unresectable visible dysplasia
  • Colorectal adenocarcinoma on biopsy
• Patients with primary sclerosing cholangitis (PSC) have earlier and higher CRC risk

3. Massive GI Hemorrhage

• Colonic mucosal ulceration exposes submucosal vessels, leading to massive haemorrhage (less common now with better medical therapy)

4. Severe Extraintestinal Manifestations

• Certain extraintestinal manifestations (e.g., pyoderma gangrenosum, some eye and joint complications) may improve with colectomy
• However, some extraintestinal diseases (e.g., ankylosing spondylitis, PSC) follow an independent course from colitis

Surgical Options

OPTION 1: Total Abdominal Colectomy (TAC) with End Ileostomy

• Toxic megacolon
• Severe medically refractory disease requiring hospitalization
• Acute severe UC not responding to IV steroids or biologics
• Colonic perforation
• Massive haemorrhage

• Removes the entire colon from the terminal ileum to the rectosigmoid junction
• Rectum is left in situ (intentionally)
• Terminal ileum is brought to the skin as an end ileostomy in the right lower quadrant (must be "Brooked"/everted above skin level for good appliance fit)
• Rectosigmoid stump is either:
  • Stapled and left intraabdominally (Hartmann's stump)
  • Brought to skin as a mucous fistula (if bowel is edematous and staples may not hold)

• Reduces risk of complicated pelvic dissection in setting of severe inflammation
• Preserves option for future ileal pouch (IPAA) - the rectal mucosa partially heals
• Shorter, safer operation (2-3 hours)

OPTION 2: Total Proctocolectomy (TPC) with Permanent End Ileostomy

• Chronic refractory disease (not hospitalized, not on high-dose steroids, no malnutrition)
• Dysplasia or CRC
• Patient declines or is not suitable for ileal pouch
• Frail patients/elderly who cannot tolerate IPAA complications
• Anal sphincter dysfunction or anorectal disease

• Removes the entire colon + rectum + anus in one operation
• Total abdominal colectomy + proctectomy via intersphincteric dissection
• Permanent end ileostomy in right lower quadrant

• Posterior dissection: between mesorectum and fascia propria of rectum
• Superior hypogastric plexus identified and preserved (autonomic nerve preservation)
• Anterior dissection: between rectum and prostate/vagina - stay on the rectal side to avoid entering Denonvilliers' fascia (risk of sexual dysfunction in men)
• Lateral rectal stalks divided bilaterally
• Perineal dissection: intersphincteric groove approach (leaves external sphincter intact for better perineal wound healing)
• Perineum closed in layers; presacral closed suction drains left in place

OPTION 3: Restorative Proctocolectomy - Ileal Pouch Anal Anastomosis (IPAA)

• Have good anal sphincter function
• Do not have Crohn's disease or indeterminate colitis
• Are not frail/cannot tolerate pouch complications
• Do not have significant anorectal disease

• Fecal incontinence or sphincter injury
• Anorectal fistula disease
• Indeterminate colitis (Crohn's vs. UC uncertain)
• Crohn's disease (much higher complication and pouch failure rate)
• Low rectal cancer (requiring APR)
• Frailty / inability to tolerate pelvic sepsis

1. Total abdominal colectomy + proctectomy as above (keeping the anal canal)
2. Pouch construction - the terminal ileum (30-40 cm) is fashioned into an internal reservoir:
   • J-pouch (most common) - two limbs of ileum stapled together forming a "J"
   • S-pouch - three limbs
   • W-pouch - four limbs (larger reservoir, less common)
3. Ileal pouch-anal anastomosis (IPAA): the pouch is brought down to the anal canal and anastomosed using a circular stapler; the anastomosis is checked by sigmoidoscopy (bleeding) and air insufflation (leak testing)
4. Temporary diverting loop ileostomy: created from more proximal small bowel to protect the pouch anastomosis while it heals (does not prevent pelvic sepsis but reduces its severity)
5. Loop ileostomy closure: performed ~3 months later as a separate operation; preceded by Gastrografin enema to confirm no anastomotic leak

• Expected 6-10 bowel movements per day (stool consistency improves over time as ileum adapts)
• Some urgency and minor incontinence may occur
• Pain with bowel movements is markedly reduced/eliminated
• Significant quality of life improvement for most patients

The Three-Stage vs. Two-Stage vs. One-Stage Approach

Perioperative Management

Preoperative

• Enterostomal therapist visit - mark ileostomy site before surgery (right lower quadrant, avoid skin folds, belt line, scars)
• Steroid taper - patients on long-term steroids need a taper to avoid adrenal insufficiency (do NOT abruptly stop)
• Biologics - typically discontinued prior to surgery (increased infection/anastomotic leak risk)
• Nutritional optimization - correct malnutrition; enteral/parenteral nutrition if needed
• DVT prophylaxis - UC causes inflammation-induced hypercoagulability; elevated postoperative VTE risk; start prophylaxis preoperatively
• Bowel preparation - mechanical bowel prep + oral antibiotics for elective cases
• Prophylactic IV antibiotics - cefazolin + metronidazole (Flagyl) preincision

Enhanced Recovery After Surgery (ERAS) Protocol

• Limit opioids; maximize non-opioid analgesia + regional anaesthesia
• Early ambulation
• Appropriate skin preparation (alcohol-based)
• Surgical site infection prevention bundle

Complications

Short-term

• Pelvic sepsis / anastomotic leak (most serious IPAA complication) - risk ~5-10%
• Rectal stump blowout (after TAC, if stump breakdown occurs) - leads to sepsis, requires reoperation
• Ileostomy complications - high output, retraction, prolapse, parastomal hernia
• DVT / Pulmonary embolism - elevated risk in UC
• Sexual dysfunction (nerve injury during proctectomy) - particularly erectile/ejaculatory dysfunction in men, dyspareunia in women
• Urinary dysfunction - ureteric injury, bladder dysfunction
• Infertility - pelvic adhesions post-IPAA increase infertility risk (laparoscopic approach significantly reduces this)

Long-term

• Pouchitis - most common long-term complication of IPAA (~50% of patients); treated with antibiotics (ciprofloxacin, metronidazole)
• Pouch failure (~5-10%) - requires excision and permanent ileostomy
• Small bowel obstruction - adhesions
• Stricture at anastomosis - may require dilation
• Vitamin B12 and bile salt malabsorption - terminal ileum resection/adaptation
• Persistent perineal wound - non-healing after proctectomy (uncommon)
• CRC in residual rectal mucosa / pouch - rare; requires continued surveillance

Key Summary Table